ELCC 2017 | Phase II study of Durvalumab for patients with NSCLC

David Gandara

David Gandara, MD, from the University of California, Davis, CA discusses the S1400A Lung-Map trial (NCT02766335) at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland. This trial demonstrated the effect of durvalumab on patients with non-small cell lung cancer (NSCLC). Other trials like the MYSTIC trial (NCT02453282) are awaiting results regarding the use of durvalumab for the treatment of NSCLC.

Share this video